John Hancock Life Insurance Fit Review for Kidney Disease

Research Snapshot

Why John Hancock Qualified for This Study

Questions This Section Answers

• Is John Hancock a good choice for life insurance for kidney disease?
• Why did only two AI platforms name John Hancock for kidney disease life insurance?

John Hancock qualified because two platforms named it during ranking discovery, meeting the study's minimum-mention threshold. Anthropic ranked it second; kimi ranked it sixth. The remaining five platforms evaluated John Hancock's fit but did not name it in their ranking-stage lists, so its 28.6% platform share reflects ranking-stage mentions only, not the total number of platforms that assessed it.

The company is a major multi-product life insurer. Its public pages describe term and permanent life insurance, term durations of 10, 15, 20, and 30 years, coverage amounts of $250,000 to $30 million, conversion features, and Vitality availability, all subject to underwriting and product/state variability ^[1]. John Hancock also markets the Vitality wellness program across term and permanent products ^[2].

Platform fit ratings split: anthropic, google, and kimi rated John Hancock a "good" fit for this use case; openai, deepseek, grok, and perplexity rated it "mixed." That split is the central finding of this review. The platforms that rated it "good" relied partly on broker and third-party underwriting guides describing kidney-disease rating pathways; the platforms that rated it "mixed" emphasized the absence of consumer-facing kidney-specific underwriting criteria.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for Kidney Disease

Questions This Section Answers

• Which John Hancock plan should a buyer with Stage 2 or Stage 3a CKD consider?
• Does John Hancock's Simple Term with Vitality accept applicants with kidney disease?

The most relevant offering is John Hancock term life insurance with the optional Vitality program, with permanent life and survivorship products also cited by platforms as potentially relevant ^[3]. Platforms consistently named term life with Vitality as the primary path for a kidney-disease buyer, and several also flagged universal life and survivorship life as alternatives for buyers with longer-term planning needs ^[5].

One product-specific exclusion matters. A John Hancock underwriting guide states that kidney disease or failure is not eligible for Simple Term with Vitality ^[6]. That means a CKD applicant generally cannot use the simplified path and should expect fuller underwriting, medical records, and possibly an Attending Physician Statement.

John Hancock also markets a separate Aspire program for type 1 and type 2 diabetes, with a virtual diabetes clinic and Vitality integration ^[7]. Because diabetes is a leading cause of kidney disease, platforms flagged Aspire as relevant to diabetic CKD applicants, though it is unclear from public materials whether diabetic CKD cases route through Aspire or standard underwriting ^[7].

What the AI Platforms Agreed About

Questions This Section Answers

• What do AI platforms agree on about John Hancock for kidney disease life insurance?
• Does John Hancock publish kidney-specific underwriting criteria?

Platforms agreed on several points. First, John Hancock offers term, universal, and survivorship life products with Vitality available across product types ^[10]. Second, John Hancock's underwriting evaluates renal function using blood urea nitrogen and serum creatinine, and requires medical records or an Attending Physician Statement for abnormal findings ^[13]. Third, the Vitality program is marketed as offering up to 25% premium savings for compliant participants, though savings vary by underwriting status, issue age, policy type, state, and achieved Vitality status ^[16].

Platforms also agreed that advanced kidney disease is a poor fit. Multiple platforms reported that Stage 4–5 CKD, dialysis, kidney failure, and polycystic kidney disease are excluded or declined in John Hancock product paths ^[19]. John Hancock's own content states its health program does not accept end-stage renal disease stage 4 or 5 ^[20].

A fourth area of agreement: no platform located a publicly published kidney-specific acceptance rule, eGFR threshold, or rate table from John Hancock's consumer-facing materials ^[10].

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Is John Hancock's underwriting for Stage 3a CKD actually better than other carriers?
• How much can Vitality reduce premiums for a table-rated kidney disease applicant?

The sharpest disagreement is whether John Hancock has a genuine kidney-disease underwriting advantage. Anthropic and kimi rated the fit "good," citing broker and third-party guides describing Stage 2–3a consideration with stable labs ^[23]. OpenAI, deepseek, grok, and perplexity rated it "mixed," noting that no public John Hancock source confirms a kidney-specific acceptance rule or preferred stage range ^[25].

A second uncertainty concerns Vitality discounts on table-rated cases. Anthropic flagged that John Hancock's underwriting guides do not state whether Vitality PLUS discounts apply to table-rated (adverse) kidney-disease cases or only to standard-rated applicants, and whether the reduction is multiplicative or capped ^[28]. No platform resolved this.

A third conflict involves Vitality pricing. John Hancock's public pages describe Vitality PLUS as available for as little as $2 per month, while its FAQ gives product-specific fees of 3% of annual term premium, $2 per month for single-life permanent products, and $4 per month for survivorship policies ^[29]. The applicable fee depends on the policy and rider.

A fourth uncertainty: the exact boundary between acceptable Stage 2–3a CKD and decline is not publicly specified. Platforms reported that outcomes likely depend on eGFR, proteinuria, blood pressure, diabetes, cause, and trend over time, but no eGFR or proteinuria threshold was located ^[28].

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What features does John Hancock offer that matter to a kidney disease life insurance buyer?
• Does John Hancock's Vitality program help with kidney disease management?

The features platforms most often tied to this use case are renal-function underwriting, the Vitality wellness program, the Aspire diabetes program, and term-to-permanent conversion.

On underwriting, John Hancock's guides describe evaluating renal function through BUN and serum creatinine, with outcomes ranging from Preferred to 200% table rating to decline depending on severity, age, and comorbidities ^[33]. Google's platform reported that Stage 1–2 CKD with stable function and controlled blood pressure can qualify for standard or select rates, while Stage 4–5 or active dialysis is uninsurable ^[36].

On Vitality, John Hancock says Vitality GO is included at no additional cost with eligible policies, while Vitality PLUS may provide premium savings, rewards, and discounts, with savings stated as up to 25% ^[38]. Vitality GO is not available in New York ^[38]. Vitality requires registration and, in most instances, completion of a Vitality Healthy Review to earn rewards ^[40].

On conversion, John Hancock describes term life as having the ability to convert to permanent coverage, but the exact conversion period, eligible products, underwriting requirements, and state variations should be confirmed in the policy contract ^[40].

On proteinuria, one platform reported John Hancock offers competitive rates for documented benign or orthostatic causes with a full workup ^[41]. This is platform-reported and not confirmed by a John Hancock consumer-facing source.

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does John Hancock life insurance cost per month for a buyer with kidney disease?
• What fees does John Hancock charge for Vitality PLUS on a term policy?

No applicant-specific premium can be verified from public information. Age, sex, tobacco use, coverage amount, term length, state, kidney history, laboratory data, and other health factors materially affect underwriting ^[43]. John Hancock does not provide a conventional online quote for its life-insurance policies, according to independent consumer reporting ^[44].

Known costs that are publicly stated:

Table ratings for adverse renal function were reported by platforms as ranging from 200% to decline in worst-case scenarios, though exact eGFR or proteinuria thresholds triggering those outcomes were not specified ^[45]. One platform reported table ratings for Stage 3a CKD can increase premiums 50–150% or more over standard, with Vitality potentially reducing premiums up to 25% post-issue ^[46].

Contract terms vary. Term coverage generally ends at the end of the selected term unless renewed, converted, or otherwise continued under the contract ^[43]. Vitality rewards, discounts, eligibility, and program features may change and are not guaranteed for the life of the policy ^[47]. Permanent policies may require ongoing premiums and can lapse if premiums, cash value, loans, or charges are not managed ^[43].

Best Suited For

Questions This Section Answers

• Who is John Hancock best suited for among kidney disease life insurance buyers?
• Is John Hancock worth it for a buyer with stable Stage 2 CKD and controlled blood pressure?

John Hancock is best considered for applicants with stable early-stage CKD who can qualify through fully underwritten term or permanent life insurance ^[48]. Platforms most often described the target profile as Stage 2 or Stage 3a CKD with stable kidney function trends over 12 or more months, controlled blood pressure under 140/90, and A1C under 7.0 ^[49].

It also fits buyers who value wellness rewards and may use Vitality participation to reduce eligible premiums ^[51]. Buyers who want conventional term coverage with conversion potential, or who need permanent coverage for longer-term planning, were also cited as reasonable candidates ^[48].

Diabetic applicants concerned about kidney complications were flagged as a fit for the Aspire program, which pairs with Vitality for health coaching ^[52]. One platform reported a 75% approval rate for diabetics in 2019 under Aspire, though that figure is dated and program-specific ^[54].

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose John Hancock for life insurance with kidney disease?
• Will John Hancock decline an applicant on dialysis or with Stage 4 CKD?

Applicants with Stage 3b–5 CKD, dialysis, transplant-related complications, rapidly declining kidney function, or substantial associated diabetes, hypertension, or cardiovascular disease should not treat John Hancock as a first stop without broker-led pre-underwriting ^[55]. Multiple platforms reported that Stage 4–5 CKD, kidney failure, dialysis, and polycystic kidney disease are excluded or declined in John Hancock product paths ^[57].

Buyers seeking guaranteed acceptance, a kidney-specific underwriting promise, or a firm online price before medical review are also poor fits ^[55]. John Hancock does not appear to offer guaranteed-issue whole life products for advanced CKD stages, according to one platform's review of kidney-disease-specific sources ^[61].

Buyers unwilling to engage with wellness tracking should note that Vitality discounts require active, ongoing participation; non-compliant participants receive only base Vitality GO benefits ^[56].

When Another Option May Be Better

Questions This Section Answers

• What is a better alternative to John Hancock for Stage 3b or Stage 4 kidney disease?
• Which carrier may offer better table ratings than John Hancock for Stage 2–3a CKD?

Several platforms named alternatives for specific situations. For Stage 3b CKD or later, Prudential was cited as offering Table 4 ratings where competitors may offer Table 8, and simplified or guaranteed-issue carriers such as Mutual of Omaha and AIG/Corebridge were cited for Stage 4–5 and dialysis ^[62]. For Stage 2 CKD term coverage, Banner Life was named as competitive ^[63].

For buyers who need a fast, exam-free path, another insurer with more explicit impaired-risk underwriting may be a better first stop ^[64]. For buyers who want published CKD class details before applying, a carrier with more transparent underwriting guidance may be easier to evaluate ^[64].

An independent broker who can obtain informal, anonymous pre-underwriting opinions from multiple carriers was recommended when CKD is Stage 3b or worse, unstable, dialysis-related, transplant-related, or accompanied by significant comorbidities ^[66].

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with John Hancock before signing a kidney disease life insurance contract?
• How can a buyer verify John Hancock's underwriting outcome before submitting a formal application?

Before applying, a buyer should confirm the following with John Hancock or a broker:

• Will John Hancock consider the applicant's exact CKD stage, eGFR trend, uACR or proteinuria, diagnosis date, cause, nephrologist records, medications, and most recent laboratory results ^[67]?
• What underwriting class, premium, postponement, exclusion, or decline decision is expected before submitting a formal application ^[67]?
• Is the proposed policy eligible for Vitality GO or Vitality PLUS in the buyer's state and for the exact product, rider, face amount, and term ^[67]?
• For a term policy, what is the exact Vitality PLUS fee, how is the premium discount calculated, and can the fee or discount change ^[68]?
• Does the up-to-25% Vitality PLUS discount apply to a table-rated rate class, or only to standard-rated applicants ^[69]?
• What are the exact conversion deadline, eligible permanent products, conversion pricing basis, and medical-underwriting rules ^[67]?
• If the applicant has diabetes, will the application route through Aspire or standard underwriting, and how does that affect rates ^[71]?
• Can an independent broker compare John Hancock's informal underwriting view with at least several carriers before a formal application is submitted ^[67]?

Final AI Consensus Verdict

Mixed fit. John Hancock is worth including in a multi-carrier comparison for a consumer with stable early-stage CKD, especially when term coverage and wellness rewards are attractive. It should not be treated as a proven best carrier for kidney disease because public evidence does not verify kidney-specific underwriting advantages, pricing, or acceptance rules ^[72].

Three platforms rated the fit "good" and four rated it "mixed." That split reflects a real evidence gap: broker and third-party underwriting guides describe kidney-disease rating pathways, but John Hancock's consumer-facing materials do not publish a kidney-specific acceptance rule, eGFR cutoff, or rate table. A broker-led pre-underwriting comparison is particularly important for Stage 3b–5 CKD, dialysis, transplant history, progression, or significant comorbidities ^[72].

For buyers comparing carriers across this category, the broader Life Insurance for Kidney Disease index covers how other carriers were assessed. Buyers who want to review the wider set of life insurance categories can do so separately.

How This Review Was Produced

This review synthesizes seven platform fit-research responses collected for the study date 2026-09-22. Two platforms named John Hancock during ranking discovery; all seven evaluated its fit for this use case. Platform fit ratings were: anthropic (good), deepseek (mixed), google (good), grok (mixed), kimi (good), openai (mixed), perplexity (mixed).

Citations are platform-reported evidence, not independently verified facts. Company-owned citations materially outnumber independent citations in the supplied research, so company claims should not be read as independently verified. No personal testing, customer experience, or independent verification was performed for this review.

Methodology Limitations

Several limitations apply. Platform-reported research dates differ from the authoritative run date: anthropic and deepseek reported 2026-01-15, while google, grok, kimi, openai, and perplexity reported 2026-09-22. Platform-reported dates are provenance metadata and do not independently prove freshness.

The deterministic identity audit noted that official-site retrieval failed for one or more mentions, so identity details were matched via exact-name fallback and the reported domain remains unverified. The official John Hancock homepage returned an HTTP 403 during retrieval and was not checked.

The supplied URLs were collected from platform responses and were not independently validated by the writer stage. Deepseek's research ran with search disabled, so its claims are platform-reported and require verification before being described as current facts.

No platform located a John Hancock kidney-disease underwriting table, eGFR cutoff, dialysis rule, or guaranteed CKD offer. The exact boundary between acceptable Stage 2–3a CKD and decline remains unclear from public sources. Independent rate-review information is not a substitute for an actual underwritten offer and may not reflect the buyer's age, state, coverage amount, or medical profile.